Suppr超能文献

山奈素通过抑制 NF-κB 信号通路下调 P-糖蛋白表达逆转人肝癌 BEL7402/5-FU 细胞多药耐药。

Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-κB signaling pathway.

机构信息

Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, China.

出版信息

Mol Carcinog. 2012 Feb;51(2):185-95. doi: 10.1002/mc.20789. Epub 2011 May 6.

Abstract

In this study, oroxylin A showed strong reversal potency in BEL7402/5-FU cells and the reversal fold (RF) reached 4.69. Simultaneously, rhodamine-123 accumulation assay and flow cytometry analysis demonstrated oroxylin A could increase drug accumulation. When combined with oroxylin A, 5-FU showed inducing apoptosis effect more seriously in DAPI staining experiment. Moreover, the mRNA and protein expression of multi-drug resistance gene (MDR1) were also decreased by oroxylin A. Further experiments exhibited that oroxylin A can downregulate P-gp expression through inhibiting nuclear factor-κB (NF-κB) signaling pathway, which might be the mechanism of reversal resistance of oroxylin A. In summary, oroxylin A could be a good candidate for the development of new MDR reversal agent and its reversal mechanism probably due to the suppression of P-gp expression via inhibiting NF-κB signaling pathway.

摘要

在这项研究中,黄芩素在 BEL7402/5-FU 细胞中表现出很强的逆转作用,逆转倍数(RF)达到 4.69。同时,吖啶橙蓄积实验和流式细胞术分析表明黄芩素可以增加药物蓄积。当与黄芩素联合使用时,5-FU 在 DAPI 染色实验中表现出更严重的诱导凋亡作用。此外,多药耐药基因(MDR1)的 mRNA 和蛋白表达也被黄芩素降低。进一步的实验表明,黄芩素可以通过抑制核因子-κB(NF-κB)信号通路下调 P-糖蛋白(P-gp)的表达,这可能是黄芩素逆转耐药的机制。综上所述,黄芩素可能是开发新型多药耐药逆转剂的候选药物,其逆转机制可能是通过抑制 NF-κB 信号通路抑制 P-gp 的表达。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验